Shareholders
The company is privately held and backed by a diverse group of professional investors – including the founders, the renowned cancer incubator Radforsk and the Norwegian investment company Investinor.
Hubro Therapeutics suggests that investors who wish to stay informed and follow the company’s progression subscribes to the newsletter.
Top ten investors
| Name | Ownership % | |
|---|---|---|
| 1 | Timmuno AS | 17,47 |
| 2 | Investinor Direkte AS | 16,97 |
| 3 | Canica Holding AG | 16,09 |
| 4 | Jandersen Kapital AS | 10,71 |
| 5 | Radforsk | 8,37 |
| 6 | Algot Invest AS | 8,11 |
| 7 | Integrated Innovation Consulting LLP | 5,19 |
| 8 | Morthen Thorsen Holding AS | 2,10 |
| 9 | JAG Holding AS | 1,93 |
| 10 | Vikingen AS | 1,93 |
Scroll to see the full table →
Investor relations
Inquiries can be made to the company´s IR:
Jon Amund Eriksen, CEO
Mail: jon.amund.eriksen@hubrotherapeutics.com
Phone: +47 95085914